Cargando…

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Choy, Ka-Tim, Wong, Alvina Yin-Lam, Kaewpreedee, Prathanporn, Sia, Sin Fun, Chen, Dongdong, Hui, Kenrie Pui Yan, Chu, Daniel Ka Wing, Chan, Michael Chi Wai, Cheung, Peter Pak-Hang, Huang, Xuhui, Peiris, Malik, Yen, Hui-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127386/
https://www.ncbi.nlm.nih.gov/pubmed/32251767
http://dx.doi.org/10.1016/j.antiviral.2020.104786
_version_ 1783516348941336576
author Choy, Ka-Tim
Wong, Alvina Yin-Lam
Kaewpreedee, Prathanporn
Sia, Sin Fun
Chen, Dongdong
Hui, Kenrie Pui Yan
Chu, Daniel Ka Wing
Chan, Michael Chi Wai
Cheung, Peter Pak-Hang
Huang, Xuhui
Peiris, Malik
Yen, Hui-Ling
author_facet Choy, Ka-Tim
Wong, Alvina Yin-Lam
Kaewpreedee, Prathanporn
Sia, Sin Fun
Chen, Dongdong
Hui, Kenrie Pui Yan
Chu, Daniel Ka Wing
Chan, Michael Chi Wai
Cheung, Peter Pak-Hang
Huang, Xuhui
Peiris, Malik
Yen, Hui-Ling
author_sort Choy, Ka-Tim
collection PubMed
description An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 μM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 μM in combination with emetine at 0.195 μM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.
format Online
Article
Text
id pubmed-7127386
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71273862020-04-08 Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro Choy, Ka-Tim Wong, Alvina Yin-Lam Kaewpreedee, Prathanporn Sia, Sin Fun Chen, Dongdong Hui, Kenrie Pui Yan Chu, Daniel Ka Wing Chan, Michael Chi Wai Cheung, Peter Pak-Hang Huang, Xuhui Peiris, Malik Yen, Hui-Ling Antiviral Res Article An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 μM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 μM in combination with emetine at 0.195 μM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits. Elsevier B.V. 2020-06 2020-04-03 /pmc/articles/PMC7127386/ /pubmed/32251767 http://dx.doi.org/10.1016/j.antiviral.2020.104786 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Choy, Ka-Tim
Wong, Alvina Yin-Lam
Kaewpreedee, Prathanporn
Sia, Sin Fun
Chen, Dongdong
Hui, Kenrie Pui Yan
Chu, Daniel Ka Wing
Chan, Michael Chi Wai
Cheung, Peter Pak-Hang
Huang, Xuhui
Peiris, Malik
Yen, Hui-Ling
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
title Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
title_full Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
title_fullStr Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
title_full_unstemmed Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
title_short Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
title_sort remdesivir, lopinavir, emetine, and homoharringtonine inhibit sars-cov-2 replication in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127386/
https://www.ncbi.nlm.nih.gov/pubmed/32251767
http://dx.doi.org/10.1016/j.antiviral.2020.104786
work_keys_str_mv AT choykatim remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT wongalvinayinlam remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT kaewpreedeeprathanporn remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT siasinfun remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT chendongdong remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT huikenriepuiyan remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT chudanielkawing remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT chanmichaelchiwai remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT cheungpeterpakhang remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT huangxuhui remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT peirismalik remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro
AT yenhuiling remdesivirlopinaviremetineandhomoharringtonineinhibitsarscov2replicationinvitro